RxDoctor Payments Data

Marcia Senteno, MD

Infectious Disease · Long Beach, CANPI 1770502650

Payments from drug & device makers

$13,659in general payments, 2019–2025

Across 419 payments — averaging $32.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$8K
  • Gilead$4K
  • Johnson & Johnson$614
  • EMD Serono, Inc.$586
  • Merck$417
  • AbbVie$204
  • plus $487 from 6 others

What the payments were for

  • Consulting fees$5,28039%
  • Speaking & faculty fees$490%
  • Food & beverage$8,31961%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,659 in reported general payments places this provider in the 80th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$39,882
Medicare patients
139
Services billed
395

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala643$2,516,072
DovatoDolutegravir Sodium/Lamivudine296$877,294
TivicayDolutegravir Sodium238$629,132
DescovyEmtricitabine/Tenofov Alafenam258$543,642
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf91$423,268
CabenuvaCabotegravir/Rilpivirine60$341,149
OdefseyEmtricitab/Rilpiviri/Tenof Ala85$295,099
JulucaDolutegravir/Rilpivirine76$278,164
PrezcobixDarunavir/Cobicistat114$278,087
IsentressRaltegravir Potassium120$230,318
RukobiaFostemsavir Tromethamine24$228,052
TriumeqAbacavir/Dolutegravir/Lamivudi51$191,431
PifeltroDoravirine83$139,147
GenvoyaElviteg/Cob/Emtri/Tenof Alafen31$117,791
Isentress HdRaltegravir Potassium58$107,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$3,730$3,177,505932 claims
Viiv Healthcare CompanyDovato, Tivicay, Cabenuva, Juluca, Rukobia$7,622$2,545,222745 claims
MerckIsentress, Pifeltro, Isentress Hd, Januvia, Dulera$417$497,287307 claims
Johnson & JohnsonPrezcobix$614$278,087114 claims
GSKTrelegy Ellipta, Breo Ellipta$52$13,06126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 856 infectious disease providers in California.

Other infectious disease in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →